Mercer Global Advisors Inc Genmab A/S Transaction History

Mercer Global Advisors Inc

$48.3 Billion
Q2 2025

A detailed history of Mercer Global Advisors Inc transactions in Genmab A/S stock. As of the latest transaction made, Mercer Global Advisors Inc holds 32,467 shares of GMAB stock, worth $932,127. This represents 0.0% of its overall portfolio holdings.

Number of Shares

32,467

Previous 50,159 35.27%

Holding current value

$932,127

Previous $982,000 31.77%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$17.98 - $23.09 $318,102 - $408,508	-17,692 Reduced 35.27%	32,467 $670,000
Q1 2025 May 15, 2025	BUY	$18.69 - $24.14 $547,916 - $707,688	29,316 Added 140.65%	50,159 $982,000
Q4 2024 Feb 14, 2025	SELL	$20.02 - $24.15 $96,176 - $116,016	-4,804 Reduced 18.73%	20,843 $434,000
Q3 2024 Nov 13, 2024	SELL	$23.84 - $28.48 $6,603 - $7,888	-277 Reduced 1.07%	25,647 $625,000
Q2 2024 Aug 12, 2024	SELL	$25.13 - $30.27 $83,909 - $101,071	-3,339 Reduced 11.41%	25,924 $651,000
Q1 2024 May 15, 2024	SELL	$26.43 - $32.77 $434,747 - $539,033	-16,449 Reduced 35.98%	29,263 $875,000
Q4 2023 Feb 14, 2024	SELL	$27.94 - $35.44 $278,058 - $352,698	-9,952 Reduced 17.88%	45,712 $1.46 Million
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $41,301 - $49,463	1,171 Added 2.15%	55,664 $1.96 Million
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $118,333 - $135,862	3,164 Added 6.16%	54,493 $2.07 Million
Q1 2023 May 15, 2023	SELL	$34.88 - $43.22 $148,030 - $183,425	-4,244 Reduced 7.64%	51,329 $1.94 Million
Q4 2022 Feb 08, 2023	BUY	$33.8 - $47.06 $5,813 - $8,094	172 Added 0.31%	55,573 $2.36 Million
Q3 2022 Nov 15, 2022	BUY	$31.52 - $373.61 $26,098 - $309,349	828 Added 1.52%	55,401 $1.78 Million
Q2 2022 Aug 10, 2022	SELL	$26.83 - $38.57 $483,503 - $695,069	-18,021 Reduced 24.82%	54,573 $1.77 Million
Q1 2022 May 10, 2022	SELL	$30.95 - $39.68 $894,888 - $1.15 Million	-28,914 Reduced 28.48%	72,594 $2.63 Million
Q4 2021 Feb 04, 2022	SELL	$35.87 - $47.12 $456,732 - $599,978	-12,733 Reduced 11.15%	101,508 $4.02 Million
Q3 2021 Nov 10, 2021	SELL	$41.55 - $48.72 $999,776 - $1.17 Million	-24,062 Reduced 17.4%	114,241 $4.99 Million
Q2 2021 Aug 10, 2021	SELL	$32.88 - $44.57 $688,046 - $932,671	-20,926 Reduced 13.14%	138,303 $5.65 Million
Q1 2021 May 11, 2021	BUY	$30.92 - $44.4 $597,467 - $857,941	19,323 Added 13.81%	159,229 $5.23 Million
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $1.69 Million - $2.05 Million	50,204 Added 55.97%	139,906 $5.69 Million
Q3 2020 Dec 10, 2020	BUY	$33.07 - $38.68 $1.62 Million - $1.9 Million	49,111 Added 120.99%	89,702 $3.28 Million
Q2 2020 Aug 10, 2020	BUY	$20.05 - $33.89 $435,064 - $735,379	21,699 Added 114.86%	40,591 $1.38 Million
Q1 2020 May 18, 2020	BUY	$17.15 - $25.22 $323,997 - $476,456	18,892 New	18,892 $400,000

Others Institutions Holding GMAB

# of Institutions

253

Shares Held

65.6M

Call Options Held

32.5K

Put Options Held

55K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $18.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.

Account

Mercer Global Advisors Inc Genmab A/S Transaction History